Research Article
The CEDAR Study: A Longitudinal Study of the Clinical Effects of Conventional DMARDs and Biologic DMARDs in Australian Rheumatology Practice
Table 1
Patient demographics and disease characteristics.
| | | Mean | SD | Min–max |
| Age (years) | 12,526 | 61.9 | 14.0 | 18.0–100.0 | cDMARDs | 11,511 | 61.8 | 13.9 | 18.0–99.0 | bDMARDs | 3,697 | 59.0 | 13.1 | 19.0–91.0 | Disease duration (years) | 9,069 | 11.1 | 10.6 | 0–77.4 | cDMARDs | 8,591 | 11.1 | 10.6 | 0–77.4 | bDMARDs | 2,387 | 13.7 | 10.5 | 0.3–61.1 | DAS28-ESR | 7,112 | 3.2 | 1.6 | 0–8.8 | cDMARDs | 6,728 | 3.2 | 1.6 | 0–8.8 | bDMARDs | 2,576 | 3.4 | 1.7 | 0–8.7 | Tender joint count | 8,842 | 3.6 | 5.6 | 0–28.0 | cDMARDs | 8,285 | 3.6 | 5.5 | 0–28.0 | bDMARDs | 3,057 | 4.4 | 6.3 | 0–28.0 | Swollen joint count | 8,842 | 3.6 | 5.5 | 0–28.0 | cDMARDs | 8,285 | 3.7 | 5.5 | 0–28.0 | bDMARDs | 3,057 | 4.2 | 6.1 | 0–28.0 | Rheumatoid factor | 4,115 | 137.4 | 297.5 | 0–5088.0 | cDMARDs | 3,846 | 139.4 | 300.0 | 0–5088.0 | bDMARDs | 1221 | 158.9 | 344.1 | 0–4886.0 | ACPA | 2282 | 110.5 | 198.3 | 0–2000.0 | cDMARDs | 2137 | 110.5 | 193.0 | 0–2000.0 | bDMARDs | 726 | 124.7 | 210.4 | 0–1816.0 |
|
|
SD = standard deviation; patients taking at least one cDMARD; patients taking at least one bDMARD.
|